ERBB2 and gastric cancer: The ongoing MOUNTAINEER02 (NCT04499924) trial is investigating tucatinib plus trastuzumab, ramucirumab and paclitaxel in second-line treatment of advanced HER2-positive gastric cancer after progression to anti-HER2 targeted first-line therapy [108].